VentureBeat

The third-largest video site in China, 56.com, has been offline for nearly a month due to what most observers believe is government censorship. But that’s not stopping rivals from raising more funding.

Youku, approximately tied with Tudou as the largest video site in the country, has just closed a $30 million round led by private equity firm Maverick Capital, with participation from existing venture and private equity investors.

A much smaller rival, called ku6.com, has also raised $30 million from undisclosed investors, according to Pacific Epoch.

Neither Youku (homepage screenshot, above) and ku6.com appear to be at serious risk of being shut down due to censorship. The Chinese government introduced a new regulation last winter that required all online video sites to receive a license to legally operate that requires they be at least half-owned by a government entity.

Ku6 and many other smaller online video sites have received approval but Youku, Tudou and 56.com haven’t.

Youku has close connections to powerful media companies and investors in China. Besides an hour’s worth of downtime a month ago, it hasn’t had any issues, and most expect it to stay on the right side of local laws. Likewise, Tudou may be safe, according to one report, because it voluntarily went offline to clean objectionable content for a day in March, after being approached by government censors. Meanwhile, 56.com is still offline — some rumors of its shut-down included that it was showing videos of the recent Chinese earthquake that the government didn’t want to be public and that it was too slow to respond to government take-down requests.

Facebook, meanwhile, experienced unexplained downtime in China yesterday.

Ku6.com (homepage screenshot, below) received a $10 million from investors including Chinese internet conglomerate Baidu, Draper Fisher Jurvetson and DT Capital Partners in May of 2007. The company also raised another round sometime at the end of last year, separate from this latest round, according to Pacific Epoch.

Youku has raised a total of $50 million, including $10 million in debt, prior to this latest round, bringing the total raised to $80 million — near what Tudou has also raised. All existing investors in Youku participated in the round — showing the level of confidence everyone seems to be feeling despite the 56.com shutdown — and including Brookside Capital, Sutter Hill Ventures, Farallon Capital, and Chengwei Ventures.

In another sign suggesting Youku will stay live, it has announced content distribution deals with more than 100 traditional media organization including Shanghai TV, Beijing TV, Jiangsu TV, China Film Group, Huayi Music, Universal Music, EMI Music, and others. The company already syndicates regional Chinese television programs. As the Chinese government already regulates traditional media, these moves can only make the site look more legitimate to censors.

Youku, like Tudou, claims to be the largest site in the country. Citing third party reports from Chinese web measurement services like iResearch, Baidu user index and Data Center of China’s Internet, and others, Youku has says it is getting more than 100 million unique visitors per month with each user spends about 300 minutes per month on the site — although many in China questions the validity of third party data tracking in the country.

Also, operating a video site is expensive, anywhere. We’ve previously heard that Youku and Tudou are spending more than one million dollars per month on video infrastructure costs, so this funding should be enough to last them for more than a year as they continue to figure out sustaining business models. Youku’s funding today will also be used to build out its sales and marketing team, to help it start making more money, the company says.

With censorship out of the way, maybe, for most Chinese video sites, the twin issues of web traffic measurement and online video monetization are the monsters left for these companies to slay. Both are still large and unresolved problems in the Chinese internet world.

Here’s the latest action:

Mobile enthusiast gives up on “mobile web” – Russell Beattie, a Silicon Valley developer and mobile enthusiast who spent two years working at Yahoo Mobile before launching a start-up called Mowser, has given up on the mobile sector. He writes: “The general answer is that I don’t actually believe in the ‘Mobile Web’ anymore, and therefore am less inclined to spend time and effort in a market I think is limited at best, and dying at worst. I’m talking specifically about sites that are geared 100% towards mobile phones and have little to no PC web presence. Two years ago I was convinced that the mobile web would continue to evolve in the West to mimic what was happening in countries like Japan and Korea, but it hasn’t happened, and now I’m sure it isn’t going to.” Mowser focused on adapting content for mobile phones. Beattie said the expected traffic never came. His story is a cold shower for industry players hoping advances by the iPhone and the Android will inject life into the sector.

Credit crunch hits cleantech after all — Despite some crowing from the clean-technology crowd that the credit crunch hadn’t hit it, it did eat into one a that sector clean-technology companies: private equity investment. Earth2Tech has a good wrapup of the numbers and commentary.

Silicon Valley’s giants are fine, but maybe not for long — The big tech companies of Silicon Valley, on the other hand, are humming along as if the current (probable) recession weren’t even taking place, says the San Jose Mercury News in its annual SV150 issue. The reason: Their international business divisions are going strong. However, the New York Times reports that housing markets worldwide are following the US market’s tailspin, so credit and spending abroad could suffer as well, challenging even multinational companies.

Feed your tank, starve a poor person — Biofuels have pushed back the fight against poverty by seven years and may continue to hurt poor people, according to a quote from World Bank president Robert Zoellick in the Guardian. The tapping of biofuels for alternative energy has faced a growing negative reaction, because it is sending food prices soaring around the world. Biofuels are made from food crops like corn and sugar, and so are taking away from the food stock. The effect, at least for the moment, will probably be limited to more cautious government subsidization policies.

Farecast rumored sold for over $75M — Online travel search site Farecast may have been sold for over $75 million, according to John Cook of the Seattle PI. He’s not sure who the buyer is, but speculates that Expedia would be a likely match since two major competitors, SideStep and Kayak, merged last year. Farecast has done well with its feature that lets you predict whether fares are going up or down in the near future, helping you decide when to buy.

Radio One buys Community Connect for $38M — Media giant Radio One has laid down $38 million for Community Connect, which operates niche sites based on ethnicity, religion and sexual orientation. The company had taken funding from Dominion Ventures, ConnectCapital, Comcast Interactive Capital and Jump Ventures, according to peHUB.

YouTube dominates video, while Google roars in search — YouTube boasted 73.18 percent of all U.S. visits among a group of 68 online video websites in March, according to Hitwise. MySpaceTV received the second highest percentage of visits, with 9.21 percent followed by Google Video with 4.06 percent. YouTube dominates video more than Google dominates search. But then search makes much more money. Google got 67.3 percent market share for search, and that’s a high, while Yahoo and Microsoft hit new lows.

Gawker media cuts Wonkette and others loose — Gawker owner Nick Denton tells Silicon Alley Insider that as the economy stumbles, he’s ditching three “underperforming” Gawker sites: Wonkette, Gridskipper and Idolator, which will all continue under new ownership. That leaves the company to focus on its 12 “core titles,” like Silicon Valley’s beloved gossip blog Valleywag.

Google App Engine and Amazon web services, together at last — When Google launched its Engine App a week ago, allowing developers to build and deploy web applications on Google infrastructure, the move was widely seen as a move against Amazon’s web services. But just because they’re competing products doesn’t mean they can’t work together, as Portland entrepreneur Chris Anderson has shown by creating AppDrop, which allows you to build apps with Google’s software development kit and deploy in Amazon’s Elastic Compute Cloud. There have been complaints that Google Engine App locks in your applications, but AppDrop shows that isn’t quite true.

LiveUniverse reportedly acquires home page service Pageflakes — LiveUniverse, the online entertainment network run by former MySpace executive Brad Greenspan, has acquired the Ajax home page service Pageflakes, according to TechCrunch’s unidentified sources. Just a few hours earlier, GigaOM reported that Pageflakes was “desperately” seeking a buyer. Last February, a number of sites said that LiveUniverse purchased video site Revver, so the network appears to be in an acquisitive mood.

Real Time Worlds confirmed today that it has raised $50 million in venture capital to fund its online gaming ventures. The Dundee, Scotland video game studio will use the second round of funding to develop games such as All Points Bulletin, a massively multiplayer online game.

The round was led by Maverick Capital and existing investors New Enterprise Associates and WPP also participated. Real Time Worlds is run by founder David Jones, the creator of the original Grand Theft Auto game that has become one of the biggest video game franchises of all time.

The company has more than 200 game developers on staff and it produced the hit Xbox 360 console game “Crackdown,” its debut title, in 2007. The game sold more than 1.4 million units, which means it generated roughly $84 million at retail.

(UPDATED at 7:40pm PT: See below.)

Featured companies: Adnexus Therapeutics, BioForm Medical, Confirma, Cardiovascular Systems, Mirabilis Medica, Neuromed Pharmaceuticals, PlaCor, Seno Medical Instruments, Vibrynt

BioForm Medical files $115M IPO for “medical aesthetics” — BioForm Medical, a San Mateo, Calif., developer of wrinkle fillers and other products for cosmetic procedures, filed to raise $115 million in an initial offering. BioForm’s major customers are plastic surgeons and dermatologists.

BioForm, however, takes pains to describe itself differently on its Web site. There, BioForm says it is “a privately-held medical device company developing and commercializing injectable implant products for soft and hard tissue augmentation.” It goes on to note that its main product, Radiesse, is marketed for “radiographic tissue marking, vocal cord insufficiency, craniofacial augmentation, and outside of the U.S for facial soft tissue augmentation.”

That all sounds pretty serious — nothing like expensive wrinkle treatments, right? But in its IPO filing, where stretching the truth could get it in trouble with the SEC, BioForm describes itself straightforwardly as “a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient’s appearance.” As for Radiesse, it notes that “[w]e obtained FDA pre-market approval, or PMA, for our key commercial application of Radiesse, the correction of moderate to severe facial wrinkles and folds in December 2006.”

BioForm is not profitable, and its losses have widened over the past three years, although sales have increased over that period. The company accumulated a net loss of $35.2 million from 2005 to 2007 (its fiscal year ends June 30).

Stealthy Vibrynt raises $16M for medical devices — Vibrynt, a Mountain View, Calif., medical-device maker that has just spun out of the ExploraMed device incubator, raised $16 million in a first funding round, VentureWire reports (subscription required), citing regulatory filings. Investors included New Enterprise Associates and Delphi Ventures; NEA backs ExploraMed.

The financing closed in April. Vibrynt doesn’t have a Web site and hasn’t yet disclosed details about its technology.

Cardiovascular Systems raises $12.5M against peripheral artery disease — Cardiovascular Systems, a St. Paul, Minn., device maker focused on the removal of arterial plaque, raised $12.5 million in a still-open extension of its first funding round, VentureWire reports. The funding reportedly came from “some” of the company’s original investors, a group that includes Easton Capital Group, Maverick Capital, Mitsui & Co. Venture Partners and ITX Institutional Holdings.

Cardiovascular Systems has developed a device that essentially “sands” artery-blocking deposits known as plaque from the inside surfaces of blood vessels. The catheter-based device uses a rotating, diamond-coated head to scrub plaque from arteries. The company told VentureWire it is anticipating FDA clearance of the device within the next few weeks.

Mirabilis Medica gets $10.5M for fibroid treatment — Seattle’s Mirabilis Medica, a medical-device company focused on women’s health, raised $10.5 million in an extension to its first funding round. Investors included Arboretum Ventures, Split Rock Partners, Dow Venture Capital, and an individual investor.

Mirabilis Medica uses high-intensity, focused ultrasound to destroy tumors such as uterine fibroids by denaturing cellular proteins and causing cells to collapse into piles of goo. The company says the device may ultimately useful in other applications as well, but hasn’t yet specified them.

Confirma gets $2 million for medical-image analysis — Bellevue, Wash.-based Confirma, a maker of computer systems that automate the interpretation of medical images, raised $2 million in bridge financing on its way to a potential $15 million third round, VentureWire reports. Fluke Venture Partners provided the funding. Confirma’s first product analyzes MRI breast scans, and the company plans to launch a similar system for prostate MRIs later this year.

PlaCor receives $3.5M for blood diagnostics — Plymouth, Minn.-based PlaCor, which just named a new CEO yesterday (see the last item in our briefing here), has also raised $3.5 million in a second funding round, VentureWire reports. Funding was provided by “accredited angel investors,” the company told VentureWire. PlaCor develops diagnostic tests of platelet reactivity, which can help physicians monitor patient response to blood-thinning drugs that help prevent or break up clots.

Neuromed raises $53M, some from mystery investors – Vancouver’s Neuromed Pharmaceuticals, battered earlier this month after it discontinued work on a new pain drug in collaboration with Merck (see our coverage in the third item of this daily briefing), raised $53.3 million in a fifth funding round. The company didn’t disclose the lead investors or new investors in the round, acknowledging only “significant participation” from existing investors including MPM Capital, James Richardson & Sons, Neuro Discovery LP, GrowthWorks Capital (Working Opportunity Fund), BDC Venture Capital, CMDF, and the Royal Bank of Canada.

Neuromed, whose partnership with Merck continues, also recently licensed another experimental pain drug from a J&J subsidiary. BioWorld has more here.

Adnexus files for $86M IPO to develop new targeted biologics — Adnexus Therapeutics, a Waltham, Mass., biotech working on a new class of drugs it calls “Adnectins,” filed to raise as much as $86.25 million in an IPO. The company’s Adnectin drug candidates are engineered proteins derived from human fibronectin, a natural protein that plays a role in wound healing and binding cell receptor proteins.

Adnexus has seven drug candidates in development, only one of which has proceeded to human testing. The company intends to target cancer and other conditions such as autoimmune and neurodegenerative disease. (See our earlier coverage of the company in the fourth item of this daily briefing.)

Seno receives $2M for early cancer detection — Seno Medical Instruments, a San Antonio, Tex., device maker focused on early cancer detection, received $2 million from the Texas Emerging Technology Fund. Seno is developing “opto-acoustic” technology designed to indicate the presence of new blood vessels that feed tumors.

UPDATE (10:15am PT): Added items on Mirabilis Medica, Confirm and PlaCor.

UPDATE REDUX (7:40pm PT): Added items on Neuromed, Adnexus and Seno.